The expression and the clinical significance of monocarboxylate transporter 4 in colorectal cancer
MENG Tao1 ZHANG Yangmei2 ZHANG Youwei2 WANG Xiang2 JIAO Nanlin3
1.Department of Nuclear Medicine, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221009, China;
2.Department of Medical Oncology, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221009, China;
3.Department of Pathology, Yijishan Hospital of Wannan Medical College, Anhui Province, Wuhu 241001, China
Abstract：Objective To explore the expression and the clinical significance of monocarboxylic acid transporters (MCTs) in colorectal cancer (CRC). Methods The expression status and clinical significance of MCT1-4 in CRC tissues were analyzed online by GEPIA2 database. Fifty-three cases of CRC tissue specimen wax blocks of Xuzhou Central Hospital in 2019 were selected, and the expression of MCT4 protein was detected by immunohistochemistry. The results of positron emission computed tomography (PET/CT) were obtained from the patients before operation. Results In the cancer genome atlas project (TCGA) database, only the expression of MCT4 mRNA in colon adenocarcinoma (COAD) tissues (275 cases) and rectal adenocarcinoma (READ) tissues (92 cases) were significantly higher than that in normal tissues, and the differences were statistically significant (P ＜ 0.05). High expression of MCT4 was associated with poor disease-free survival (DFS) in patients with CRC (P ＜ 0.05). Moreover, the expression of MCT4 protein in CRC tissue was significantly higher than that in normal tissue, and the difference was highly statistically significant (P ＜ 0.01). For patients with high expression of MCT4, the standardized uptake value (SUV) of 18-fluorodeoxyglucose (18F-FDG) on PET/CT was higher than that of low expression of MCT4, and the difference was highly statistically significant (P ＜ 0.01). Conclusion MCT4 plays an important role in the development of CRC and is expected to become a new therapeutic target.
[1] Gu MJ，Huang QC，Bao CZ，et al. Attributable causes of colorectal cancer in China [J]. BMC Cancer，2018，18（1）：38.
[2] Zhu J，Tan Z，Hollis-Hansen K，et al. Epidemiological Trends in Colorectal Cancer in China：An Ecological Study [J]. Dig Dis Sci，2017，62（1）：235-243.
[3] Li Z，Wu Q，Sun S，et al. Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets [J]. Biochem Biophys Res Commun，2018，501（4）：962-967.
[4] 陈哲文，张杰，王正平，等.单羧酸转运载体与肿瘤代谢的关系[J].肿瘤代谢与营养电子杂志，2019，6（2）：266-271.
[5] Payen VL，Mina E，Van Hée VF. Monocarboxylate transporters in cancer [J]. Mol Metab，2019，pii：S2212-8778（19）30403-X.
[6] Yuan Y，Sun S，Jiao N，et al. Upregulation of HOXA10 Protein Expression Predicts Poor Prognosis for Colorectal Cancer [J]. Genet Test Mol Biomarkers，2018，22（6）：390-397.
[7] Vanhove K，Graulus GJ，Mesotten L，et al. The Metabolic Landscape of Lung Cancer：New Insights in a Disturbed Glucose Metabolism [J]. Front Oncol，2019，9：1215.
[8] Gill KS，Fernandes P，O′Donovan TR，et al. Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response [J]. Biochim Biophys Acta，2016， 1866（1）：87-105.
[9] Duan K，Liu ZJ，Hu SQ，et al. Lactic acid induces lactate transport and glycolysis/OXPHOS interconversion in glioblastoma [J]. Biochem Biophys Res Commun，2018， 503（2）：888-894.
[10] 胡媛，曾飞.G蛋白偶联受体81、单羧酸转运体1和4在宫颈鳞癌中的表达及其临床意义[J].中南大学学报：医学版，2018，43（9）：950-956.
[11] Benjamin D，Robay D，Hindupur SK，et al. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells [J]. Cell Rep，2018，25（11）：3047-3058.
[12] Park SJ，Smith CP，Wilbur RR，et al. An overview of MCT1 and MCT4 in GBM：small molecule transporters with large implications [J]. Am J Cancer Res，2018，8（10）：1967-1976.
[13] Guo C，Huang T，Wang QH，et al. Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation，migration，and invasion of renal cancer cells [J]. Cancer Cell Int，2019，19：170.
[14] Contreras-Baeza Y，Sandoval PY，Alarcón R，et al. Monocarboxylate transporter 4 （MCT4） is a high affinity transporter capable of exporting lactate in high-lactate microenvironments [J]. J Biol Chem，2019，294（52）：20135-20147.
[15] Choi SY，Xue H，Wu R，et al. The MCT4 Gene：A Novel，Potential Target for Therapy of Advanced Prostate Cancer [J]. Clin Cancer Res，2016，22（11）：2721-2733.
[16] Chen HL，OuYang HY，Le Y，et al. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy [J]. Cancer Med，2018，7（11）：5339-5350.
[17] Todenh?觟fer T，Seiler R，Stewart C，et al. Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer [J]. Mol Cancer Ther，2018，17（12）：2746-2755.
[18] Pinheiro C，Longatto-Filho A，Scapulatempo C，et al. Increased expression of monocarboxylate transporters 1，2 and 4 in colorectal carcinomas [J]. Virchows Arch，2008， 452（2）：139-146.
[19] Kim HK，Lee I，Bang H，et al. MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis [J]. Mol Cancer Ther，2018，17（4）：838-848.
[20] Martins SF，Amorim R，Viana-Pereira M，et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer，lymph node and hepatic metastasis [J]. BMC Cancer，2016，16：535.
[21] Abe Y，Nakayama Y，Katsuki T，et al. The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer [J]. Asia Pac J Clin Oncol，2019，15（2）：e49-e55.
[22] 刘德峰，朱峰，王冠民，等.18F-FDG PET/CT对非小细胞肺癌患者临床分期的诊断价值及对治疗的指导作用[J].癌症进展，2018，16（15）：1854-1860.
2020, Vol. 17 
京公网安备 11010502046598号